GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medicus Pharma Ltd (OTCPK:MDPLF) » Definitions » Debt-to-EBITDA

Medicus Pharma (Medicus Pharma) Debt-to-EBITDA : 0.00 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Medicus Pharma Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Medicus Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Medicus Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Medicus Pharma's annualized EBITDA for the quarter that ended in Dec. 2023 was $-11.39 Mil. Medicus Pharma's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Medicus Pharma's Debt-to-EBITDA or its related term are showing as below:

MDPLF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.31   Med: -0.83   Max: -0.34
Current: -0.38

During the past 3 years, the highest Debt-to-EBITDA Ratio of Medicus Pharma was -0.34. The lowest was -1.31. And the median was -0.83.

MDPLF's Debt-to-EBITDA is ranked worse than
100% of 655 companies
in the Drug Manufacturers industry
Industry Median: 1.66 vs MDPLF: -0.38

Medicus Pharma Debt-to-EBITDA Historical Data

The historical data trend for Medicus Pharma's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicus Pharma Debt-to-EBITDA Chart

Medicus Pharma Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-EBITDA
-0.34 -1.31 -

Medicus Pharma Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only -2.64 -1.47 -2.38 - -

Competitive Comparison of Medicus Pharma's Debt-to-EBITDA

For the Drug Manufacturers - General subindustry, Medicus Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicus Pharma's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medicus Pharma's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Medicus Pharma's Debt-to-EBITDA falls into.



Medicus Pharma Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Medicus Pharma's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -6.045
=0.00

Medicus Pharma's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -11.392
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Medicus Pharma  (OTCPK:MDPLF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Medicus Pharma Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Medicus Pharma's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Medicus Pharma (Medicus Pharma) Business Description

Comparable Companies
Traded in Other Exchanges
Address
100 King Street West, Suite 3400, One First Canadian Place, Toronto, ON, CAN, M5X 1A4
Medicus Pharma Ltd will carry on the business of pharmaceutical drug development focused initially on SkinJect. The objective of SkinJect is developing and commercializing novel microneedle arrays for the purpose of treating certain skin cancers, initially basal cell carcinoma.

Medicus Pharma (Medicus Pharma) Headlines

From GuruFocus

Medicus Pharma Opens the Market

By PRNewswire 10-26-2023